Juvena Therapeutics
Palo Alto
About Juvena Therapeutics
Juvena Therapeutics develops biologic drug candidates by identifying and engineering human stem cell-secreted proteins into therapies that aim to restore tissue homeostasis and improve muscle and metabolic function. It uses a proprietary, AI-enabled discovery platform that maps the therapeutic potential of the secretome to disease phenotypes and advances selected proteins into engineered biologic medicines. The company’s pipeline includes engineered proteins for muscle regeneration and metabolic indications, with its lead candidate being evaluated in clinical studies for muscle-related disease. Juvena collaborates with partners to expand discovery efforts and explore new therapeutic targets using its computational and biological capabilities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $113.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: juvenatherapeutics.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/juvena-therapeutics-23299 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.